Cargando…
The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial
Background: Fatigue is a common complication associated with multiple sclerosis (MS). The aim of this study was to evaluate the impact of dalfampridine and amantadine on fatigue in patients with MS. Methods: This was a randomized, double-blind, clinical trial on patients with MS. The recruited patie...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Tehran University of Medical Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189202/ https://www.ncbi.nlm.nih.gov/pubmed/38011342 http://dx.doi.org/10.18502/cjn.v21i4.11717 |
_version_ | 1785043035397029888 |
---|---|
author | Sadeqi, Yasaman Baghbanian, Seyed Mohammad Bazi, Aliyeh Ghazaeian, Monireh Fallah, Sahar |
author_facet | Sadeqi, Yasaman Baghbanian, Seyed Mohammad Bazi, Aliyeh Ghazaeian, Monireh Fallah, Sahar |
author_sort | Sadeqi, Yasaman |
collection | PubMed |
description | Background: Fatigue is a common complication associated with multiple sclerosis (MS). The aim of this study was to evaluate the impact of dalfampridine and amantadine on fatigue in patients with MS. Methods: This was a randomized, double-blind, clinical trial on patients with MS. The recruited patients were adults (≥ 18 years old) diagnosed with MS; their Expanded Disability Status Scale (EDSS) was between 0.0 and 5.5, and their fatigue was confirmed by the Modified Fatigue Impact Scale (MFIS). They were randomly assigned to the amantadine (100 mg twice daily) and dalfampridine (10 mg twice daily) for eight weeks. The primary outcome was the improvement of fatigue score, and the secondary outcome was assessment of quality of life by the Short-Form Health Survey (SF-36) and any reported side effects. Results: A total of 69 patients were recruited, and 54 of them were analyzed. The mean MFIS significantly improved in both groups after one and two months compared to baseline: amantadine: first month: 40.63 ± 14.35 (P = 0.040), second month: 36.56 ± 17.12 (P = 0.010); dalfampridine: first month: 38.29 ± 15.23 (P = 0.001), second month: 34.26 ± 18.30 (P = 0.001). However, the amount of changes from baseline was not significantly different (amantadine, P = 0.090; dalfampridine, P = 0.130). The amount of changes in quality of life showed no significant improvement (P = 0.210). Conclusion: The results showed that dalfampridine was not different with amantadine in improving fatigue in patients with MS; besides, it showed an acceptable safety profile. Therefore, it can be considered as a possible beneficial therapeutic agent in MS fatigue. |
format | Online Article Text |
id | pubmed-10189202 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Tehran University of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-101892022023-05-18 The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial Sadeqi, Yasaman Baghbanian, Seyed Mohammad Bazi, Aliyeh Ghazaeian, Monireh Fallah, Sahar Curr J Neurol Original Article Background: Fatigue is a common complication associated with multiple sclerosis (MS). The aim of this study was to evaluate the impact of dalfampridine and amantadine on fatigue in patients with MS. Methods: This was a randomized, double-blind, clinical trial on patients with MS. The recruited patients were adults (≥ 18 years old) diagnosed with MS; their Expanded Disability Status Scale (EDSS) was between 0.0 and 5.5, and their fatigue was confirmed by the Modified Fatigue Impact Scale (MFIS). They were randomly assigned to the amantadine (100 mg twice daily) and dalfampridine (10 mg twice daily) for eight weeks. The primary outcome was the improvement of fatigue score, and the secondary outcome was assessment of quality of life by the Short-Form Health Survey (SF-36) and any reported side effects. Results: A total of 69 patients were recruited, and 54 of them were analyzed. The mean MFIS significantly improved in both groups after one and two months compared to baseline: amantadine: first month: 40.63 ± 14.35 (P = 0.040), second month: 36.56 ± 17.12 (P = 0.010); dalfampridine: first month: 38.29 ± 15.23 (P = 0.001), second month: 34.26 ± 18.30 (P = 0.001). However, the amount of changes from baseline was not significantly different (amantadine, P = 0.090; dalfampridine, P = 0.130). The amount of changes in quality of life showed no significant improvement (P = 0.210). Conclusion: The results showed that dalfampridine was not different with amantadine in improving fatigue in patients with MS; besides, it showed an acceptable safety profile. Therefore, it can be considered as a possible beneficial therapeutic agent in MS fatigue. Tehran University of Medical Sciences 2022-10-07 /pmc/articles/PMC10189202/ /pubmed/38011342 http://dx.doi.org/10.18502/cjn.v21i4.11717 Text en Copyright © 2022 Iranian Neurological Association, and Tehran University of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International license (https://creativecommons.org/licenses/by-nc/4.0/). Non-commercial uses of the work are permitted, provided the original work is properly cited. |
spellingShingle | Original Article Sadeqi, Yasaman Baghbanian, Seyed Mohammad Bazi, Aliyeh Ghazaeian, Monireh Fallah, Sahar The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial |
title | The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial |
title_full | The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial |
title_fullStr | The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial |
title_full_unstemmed | The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial |
title_short | The effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: A randomized, double-blind, clinical trial |
title_sort | effectiveness of amantadine and dalfampridine in improving fatigue in patients with multiple sclerosis: a randomized, double-blind, clinical trial |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189202/ https://www.ncbi.nlm.nih.gov/pubmed/38011342 http://dx.doi.org/10.18502/cjn.v21i4.11717 |
work_keys_str_mv | AT sadeqiyasaman theeffectivenessofamantadineanddalfampridineinimprovingfatigueinpatientswithmultiplesclerosisarandomizeddoubleblindclinicaltrial AT baghbanianseyedmohammad theeffectivenessofamantadineanddalfampridineinimprovingfatigueinpatientswithmultiplesclerosisarandomizeddoubleblindclinicaltrial AT bazialiyeh theeffectivenessofamantadineanddalfampridineinimprovingfatigueinpatientswithmultiplesclerosisarandomizeddoubleblindclinicaltrial AT ghazaeianmonireh theeffectivenessofamantadineanddalfampridineinimprovingfatigueinpatientswithmultiplesclerosisarandomizeddoubleblindclinicaltrial AT fallahsahar theeffectivenessofamantadineanddalfampridineinimprovingfatigueinpatientswithmultiplesclerosisarandomizeddoubleblindclinicaltrial AT sadeqiyasaman effectivenessofamantadineanddalfampridineinimprovingfatigueinpatientswithmultiplesclerosisarandomizeddoubleblindclinicaltrial AT baghbanianseyedmohammad effectivenessofamantadineanddalfampridineinimprovingfatigueinpatientswithmultiplesclerosisarandomizeddoubleblindclinicaltrial AT bazialiyeh effectivenessofamantadineanddalfampridineinimprovingfatigueinpatientswithmultiplesclerosisarandomizeddoubleblindclinicaltrial AT ghazaeianmonireh effectivenessofamantadineanddalfampridineinimprovingfatigueinpatientswithmultiplesclerosisarandomizeddoubleblindclinicaltrial AT fallahsahar effectivenessofamantadineanddalfampridineinimprovingfatigueinpatientswithmultiplesclerosisarandomizeddoubleblindclinicaltrial |